Nathan J. Dowden
President & COO · Entrada Therapeutics, Inc.
- 2025
- Sep 3, 2026
- 5
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Nathan J. Dowden files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Kush Parmar - $3.65M in TRDA purchases and sales in the last 12 months
- MPM BioVentures 2014, L.P. - $3.60M in TRDA purchases and sales in the last 12 months
- MPM BIOVENTURES 2018, L.P. - $3.60M in TRDA purchases and sales in the last 12 months
- 5AM Ventures V, L.P. - $3.00M in TRDA purchases and sales in the last 12 months
- BAKER BROS. ADVISORS LP - $1.61M in TRDA purchases and sales in the last 12 months
- Kory James Wentworth - $434K in TRDA purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Nathan J. Dowden?
Nathan J. Dowden is a corporate insider, tracked as President & COO of Entrada Therapeutics, Inc. (TRDA). InsiderAlpha holds 5 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Nathan J. Dowden submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Nathan J. Dowden been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($426K) across all tracked filings.
